Kenya: Pharmaceutical lobby to conduct study on unregulated medicines

The Kenya Association of Pharmaceutical Industry (KAPI) in collaboration with the University of Nairobi has announced plans to commission a nationwide market study to establish the prevalence of unregulated medicines in Kenya.

The research study seeks to measure the extent and degree of unregulated pharmaceutical products available in the country’s retail pharmaceutical market.

Unregulated or Free-for-all Pharmaceutical products are categorised as illicit and counterfeit products not sourced through the established channels including unregulated imports.

The study is also expected to provide a foundation for policy and enforcement interventions as the Association plans to share the study findings with the sector regulator, Kenya Revenue Authority, Ministry of Health, KAPI members as well other stakeholders once completed.